Skip to content
drillr.ai
Sign up

VKTX

Viking Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$25.05
−0.48%
Ask drillr

  • Oct 16, 2026, 22:46 UTC

    Viking Therapeutics shares closed at $25.11, down 8.26% from the previous close.

    Source:

  • Oct 9, 2026, 22:45 UTC

    Viking Therapeutics shares rose 2.88% from the previous close to settle at $28.53.

    Source:

  • Oct 8, 2026, 22:50 UTC

    Viking Therapeutics shares fell 2.84% to $27.73 from the preceding trading day.

    Source:

  • Oct 1, 2026, 22:46 UTC

    Viking Therapeutics, Inc. (VKTX) shares fell 6.41% to close at $30.51 on the most recent trading day.

    Source:

  • Sep 28, 2026, 15:12 UTC

    Kuehn Law, PLLC is investigating whether certain officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties to shareholders.

    Source:

  • Sep 24, 2026, 22:45 UTC

    Viking Therapeutics, Inc. (VKTX) shares fell 11.76% to close at $36.75, a steeper decline than the broader market.

    Source:

  • Sep 24, 2026, 15:58 UTC

    Viking Therapeutics shares fell 15.20%, or $6.33, to $35.32 on Thursday on the Nasdaq after the equity and convertible notes offering was priced.

    Source:

  • Sep 24, 2026, 14:48 UTC

    Viking Therapeutics announced a $500 million capital raise consisting of 7.86 million common shares at $35 per share and $225 million of 2.00% convertible notes due 2032.

    Source:

  • Sep 23, 2026, 22:51 UTC

    Viking Therapeutics, Inc. (VKTX) shares rose 1.96% to close at $41.65 on the latest trading day.

    Source:

  • Sep 23, 2026, 20:54 UTC

    Viking Therapeutics shares gained over 40% in two days after the company reported positive results for its weight-loss drug candidate.

    Source:

  • Sep 23, 2026, 20:32 UTC

    Viking Therapeutics announced its intention to offer $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes due 2032 in separate public offerings.

    Source:

  • Sep 22, 2026, 21:47 UTC

    Viking Therapeutics shares jumped over 35% on September 22, 2026, their best single-day performance since February 2024.

    Source:

  • Sep 22, 2026, 15:05 UTC

    Viking Therapeutics reported trial data showing its obesity drug VK2735 maintained most patients' initial weight loss with less frequent dosing, sending its shares up over 27%.

    Source:

  • Sep 22, 2026, 14:23 UTC

    Viking Therapeutics said its injectable obesity candidate remained efficacious in a Phase 2 trial after transitioning from weekly to every-other-week or monthly dosing.

    Source:

  • Sep 22, 2026, 13:31 UTC

    Viking Therapeutics shares surged 24%, marking their largest gain since October 2024.

    Source:

  • Sep 22, 2026, 12:22 UTC

    Viking Therapeutics announced positive results from its VK2735-102 maintenance therapy trial for the dual GLP-1/GIP agonist VK2735, sending its shares up 20.6% in after-hours trading.

    Source:

  • Sep 22, 2026, 11:07 UTC

    Viking Therapeutics reported positive earnings results, sending its shares up 25% in premarket trading.

    Source:

  • Sep 22, 2026, 11:05 UTC

    Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, showing 22% placebo-adjusted weight loss at week 33 with weekly 17.5 mg dosing and maintained weight loss with monthly and every-other-week regimens.

    Source:

  • Jul 29, 2026, 20:05 UTC

    Viking Therapeutics announced its financial results for the second quarter and six months ended June 30, 2026.

    Source:

  • Jun 25, 2026, 15:01 UTC

    Viking Therapeutics initiated a Phase I clinical study for its new obesity drug VK3019.

    Source:

  • Jun 11, 2026, 11:05 UTC

    Viking Therapeutics appointed Hubert C. Chen, M.D. as a new executive.

    Source: